stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) EPS (diluted)
Roivant Sciences Ltd.'s EPS (diluted) for fiscal 2026 was −$0.54, compared with −$0.24 in fiscal 2025. Over the twelve months to 30 June 2026 it was −$0.53. Over the past ten years it has ranged from −$1.42 (fiscal 2023) to $5.23 (fiscal 2024); the current reading is higher than 57% of that period. Roivant Sciences Ltd. ranks 135th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | −$0.54 | — |
| FY2025 | −$0.24 | — |
| FY2024 | $5.23 | — |
| FY2023 | −$1.42 | — |
| FY2022 | −$1.26 | — |
| FY2021 | −$1.28 | — |
| FY2020 | −$0.01 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.26 | — |
| Mar 2026 | $0.28 | — |
| Dec 2025 | −$0.38 | — |
| Sep 2025 | −$0.17 | — |
| 21 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $19.26 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| INCY Incyte Corporation compare | $1.88 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. | −$0.53 |
| INSM Insmed, Inc. compare | −$2.82 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
| RVMD Revolution Medicines, Inc. compare | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ROIV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement